- Presentations will highlight significant progress made towards development of novel therapeutic antibodies
Breda, the Netherlands and Ghent, Belgium– arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that Professor Hans de Haard (Chief Scientific Officer) and Dr. Debbie Allen (Senior Director, Business Development) will each present at the Ninth Annual PEGS (Protein Engineering Summit). The event takes place April 29-May 3, 2013 at the Seaport World Trade Center (Boston, MA, USA).
Dr. Allen will give a presentation on Monday, April 29 at 3:40pm (ET) entitled ’Functional Diversity as the Key to Choice in Human Antibody Drug Discovery’ within the Biologics Partnering Forum running in parallel with PEGS.
In her presentation, Dr. Allen will show why functional diversity, a key feature of the Company’s SIMPLE Antibody™ Platform, has been central to arGEN-X’s success in generating antibodies against the most challenging disease targets in the industry. The presentation will discuss how the discovery of diverse populations of antibodies against c-MET and IL22R have resulted in the preclinical leads ARGX-111 for solid tumor immunotherapy and ARGX-112, for treatment of chronic skin inflammation, respectively. Dr. Allen will also highlight the diversity that SIMPLE Antibody™ is generating against challenging disease targets such as G protein-coupled receptors and ion channels.
Prof. de Haard will give a presentation on Tuesday, April 30 at 11:45am (ET) entitled ‘ARGX-110, a Novel Human Anti-CD70 Antibody Functioning as an Immune Checkpoint Inhibitor and Proliferation Blocker’ as part of the ‘Antibodies in Cancer Therapy’ stream.
In his presentation, Prof. de Haard will discuss the discovery of ARGX-110 from the SIMPLE Antibody™ platform and its preclinical characterization supporting clinical development as a potential first in class product for cancer and autoimmune disease therapy. ARGX-110 is a potent modulator of CD70 function in a diverse range of solid and hematological tumors, where CD70 overexpression accompanies escape from immune surveillance and tumor cell proliferation and survival. In addition, the selective cell-killing properties of ARGX-110 have been enhanced through application of POTELLIGENT® technology licensed from BioWa, Inc. arGEN-X initiated a Phase Ib clinical trial for ARGX-110 in January 2013.
